Verastem Oncology
VSTM
$9.38
Share price
1.79%
Change (1 day)
2,305.13%
Change (1 year)
Categories
Verastem Oncology (VSTM) - P/B ratio
P/B ratio as of April 2024 : 4.15
According to Verastem Oncology
's latest financial reports the company has a price-to-book ratio of 4.15.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Verastem Oncology - P/B ratio (from 2012 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 3.58 | 100.91% |
| 2022-12-31 | 1.78 | -58.17% |
| 2021-12-31 | 4.27 | 35.97% |
| 2020-12-31 | 3.14 | -79.04% |
| 2019-12-31 | 15.0 | 650.08% |
| 2018-12-31 | 2.00 | -25.82% |
| 2017-12-31 | 2.69 | 369.34% |
| 2016-12-31 | 0.5731 | -14.54% |
| 2015-12-31 | 0.6705 | -76.11% |
| 2014-12-31 | 2.81 | 14.17% |
| 2013-12-31 | 2.46 | 24.25% |
| 2012-12-31 | 1.98 | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.61 | -61.21% | 🇺🇸 USA |
 LabCorp LH | 2.12 | -48.95% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.16 | 24.43% | 🇬🇧 UK |
 Curis CRIS | 4.40 | 6.05% | 🇺🇸 USA |